Sunshine Biopharma Current Debt
SBFMW Stock | USD 0.17 0.04 19.05% |
Sunshine Biopharma has over 657,705 in debt which may indicate that it relies heavily on debt financing. At this time, Sunshine Biopharma's Short and Long Term Debt Total is fairly stable compared to the past year. Short and Long Term Debt is likely to climb to about 4.4 M in 2024, whereas Short Term Debt is likely to drop slightly above 112.7 K in 2024. . Sunshine Biopharma's financial risk is the risk to Sunshine Biopharma stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Sunshine Biopharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Sunshine Biopharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Sunshine Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Sunshine Biopharma's stakeholders.
For most companies, including Sunshine Biopharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Sunshine Biopharma Warrant, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Sunshine Biopharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Book Value 12.515 | Operating Margin (0.13) | Profit Margin (0.13) | Return On Assets (0.11) | Return On Equity (0.18) |
Sunshine |
Sunshine Biopharma Financial Rating
Sunshine Biopharma Warrant financial ratings play a critical role in determining how much Sunshine Biopharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Sunshine Biopharma's borrowing costs.Piotroski F Score | 5 | Healthy | View |
Beneish M Score | (1.79) | Possible Manipulator | View |
Sunshine Biopharma Debt to Cash Allocation
Many companies such as Sunshine Biopharma, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Sunshine Biopharma Warrant has accumulated 657.71 K in total debt with debt to equity ratio (D/E) of 8.98, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sunshine Biopharma has a current ratio of 83.39, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Note, when we think about Sunshine Biopharma's use of debt, we should always consider it together with its cash and equity.Sunshine Biopharma Total Assets Over Time
Sunshine Biopharma Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Sunshine Biopharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Sunshine Biopharma Debt Ratio | 14.0 |
Sunshine Net Debt
Understaning Sunshine Biopharma Use of Financial Leverage
Understanding the structure of Sunshine Biopharma's debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Sunshine Biopharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last Reported | Projected for Next Year | ||
Net Debt | -15.6 M | -14.9 M | |
Short and Long Term Debt Total | 657.7 K | 1 M | |
Short Term Debt | 118.7 K | 112.7 K | |
Long Term Debt | 2.2 M | 1.2 M | |
Short and Long Term Debt | 4.2 M | 4.4 M | |
Net Debt To EBITDA | 4.09 | 4.29 | |
Debt To Equity | 0.15 | 0.16 | |
Interest Debt Per Share | 11.29 | 10.72 | |
Debt To Assets | 0.12 | 0.14 | |
Long Term Debt To Capitalization | 1.03 | 1.09 | |
Total Debt To Capitalization | 0.13 | 0.14 | |
Debt Equity Ratio | 0.15 | 0.16 | |
Debt Ratio | 0.12 | 0.14 | |
Cash Flow To Debt Ratio | (1.30) | (1.37) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.